FreeTheAI

FDA Accepts CorMedix REZZAYO Application for Priority Review with Q1 2027 Target

BullishMedium impact
CRMD$7.26 −2.68%

The U.S. Food and Drug Administration has accepted a supplemental New Drug Application for REZZAYO (rezafungin), granting it Priority Review status. Submitted by partner Mundipharma, the application seeks approval for the drug to prevent invasive fungal disease. The agency set a target action date under the Prescription Drug User Fee Act for the first quarter of 2027.

Priority Review designation shortens the standard regulatory evaluation timeline, reflecting the potential to address an unmet medical need in preventing fungal infections. The submission is backed by positive topline findings from the Phase III ReSPECT clinical trial. An expedited review allows CorMedix Inc. (CRMD) to move closer to broadening the treatment use for the therapy.

If the regulatory agency grants approval, CorMedix plans to start commercial promotional activities in the second half of 2027 to prepare for launch. Investors will monitor regulatory progress heading into the early 2027 decision window and subsequent commercial preparations.

Key points

  • The FDA accepted the supplemental application for REZZAYO for Priority Review to prevent invasive fungal disease.
  • The regulatory decision target date is set for the first quarter of 2027.
  • The filing was submitted by partner Mundipharma and supported by Phase III ReSPECT trial data.
  • CorMedix Inc. (CRMD) plans promotional activities in the second half of 2027 if approved.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did the FDA decide regarding CorMedix REZZAYO?

The FDA accepted the supplemental application for REZZAYO for Priority Review to prevent invasive fungal disease, targeting a decision in early 2027.

When could REZZAYO launch for fungal disease prevention?

If approved in the first quarter of 2027, CorMedix plans to begin promotional efforts in the second half of 2027 to prepare for launch.